Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model-Reference-Cited by-同舟云学术

Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model

Published:2021-03-18 Issue:4 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

He Miao¹,Souza Ernane¹,Matvekas Aleksas¹,Crass Ryan L.¹^ORCID,Pai Manjunath P.¹^ORCID

Affiliation:

1. College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA

Abstract

The risk of vancomycin (VAN)-associated acute kidney injury (AKI) may be altered with combination regimens. The specific AKI risk when VAN is combined with imipenem-cilastatin/relebactam (IMP-C/REL) or piperacillin/tazobactam (TZP) has not been clearly defined.

Funder

Merck

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02141-20

Reference18 articles.

1. The Nephrotoxicity of Vancomycin

2. Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults

3. Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy—What Is the Clinician to Do?